Your browser doesn't support javascript.
loading
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg, M E L; Onstenk, W; Boere, I A; Look, M; Ottevanger, P B; de Gooyer, D; Kerkhofs, L G M; Valster, F A A; Ruit, J B; van Reisen, A G P M; Goey, S H; van der Torren, A M E; ten Bokkel Huinink, D; Kok, T C; Verweij, J; van Doorn, H C.
Afiliación
  • van der Burg ME; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Onstenk W; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Boere IA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: i.boere@erasmusmc.nl.
  • Look M; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Ottevanger PB; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • de Gooyer D; Department of Internal Medicine, Franciscus Hospital, Roosendaal, The Netherlands.
  • Kerkhofs LG; Department of Internal Medicine, Admiraal de Ruyter Hospital, Vlissingen, The Netherlands.
  • Valster FA; Department of Internal Medicine, Lievensberg Hospital, Bergen op Zoom, The Netherlands.
  • Ruit JB; Department of Internal Medicine, Vlietland Hospital, Schiedam, The Netherlands.
  • van Reisen AG; Department of Internal Medicine, ZorgSaam Zeeuws-Vlaanderen, Terneuzen, The Netherlands.
  • Goey SH; Department of Internal Medicine, Tweesteden Hospital, Tilburg, The Netherlands.
  • van der Torren AM; Department of Internal Medicine, Groene Hart Hospital, Gouda, The Netherlands.
  • ten Bokkel Huinink D; Department of Internal Medicine, Diakonessenhuis, Utrecht, The Netherlands.
  • Kok TC; Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands.
  • Verweij J; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • van Doorn HC; Department of Gynecological Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Eur J Cancer ; 50(15): 2592-601, 2014 Oct.
Article en En | MEDLINE | ID: mdl-25096168
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Glandulares y Epiteliales Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Glandulares y Epiteliales Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido